[The changes of gene expression in multiple myeloma treated with thalidomide].
OBJECTIVE
To investigate the effect of thalidomide on bone marrow cells gene expression in multiple myeloma (MM) patients with suppression subtractive hybridization (SSH) and explore the molecular mechanism of thalidomide therapy for MM.


METHODS
In a MM patient receiving thalidomide therapy and bone marrow cell from himself, total RNA extraction, mRNA isolation and cDNA synthesis were carried out respectively with routine procedures. SSH were performed in A and B group respectively. The subtracted cDNA was selectively amplified by suppression PCR. The product was inserted into T vector, and then transfected into the competent host JM109. So two subtractive libraries were constructed. After blue-white screening, colonies were selected and plasmids extracted. Homologous comparation was conducted in GenBank.


RESULTS
In group A, seven clones were isolated, including ribosomal protein L19 (HUMAN), IgG lambda chain v-v region (HUMAN), contains Alu repetitive element, NADH-ubiquinone oxidoreductase chain 2, elongation factor 1-gamma, human beta globin region, and 40S ribosomal protein S4 (HUMAN). In group B, six clones were isolated, including cytochrome B, up-regulated by 1,25-dihydroxyvitamin D(3) (VDUP1), NADH- ubiquinone oxidoreductase 20 Kd subunit, mu-calpain large subunit, tumor protein, translationally-controlled 1 (TPT1) and COATOMER alpha subunit.


CONCLUSIONS
Thalidomide induces apoptosis and antiangiogenesis by down-regulating some genes and up-regulating some others genes.
Zhang
Hai-bo
HB
Department of Hematalogy of Internal Medicine, Beijing Chaoyang Hospital, Beijing 100020, China. zhb_ll@hotmail.com
Chen
Shi-lun
SL
Liu
Jing-zhong
JZ
Xiao
Bai
B
Chen
Zhen-bin
ZB
Wang
Hui-juan
HJ
D020533:Angiogenesis Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D001854:Bone Marrow Cells / Q000187:drug effects / Q000378:metabolism; D018076:DNA, Complementary / Q000096:biosynthesis; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy / Q000235:genetics*; D009693:Nucleic Acid Hybridization; D012313:RNA / Q000302:isolation & purification; D012333:RNA, Messenger / Q000302:isolation & purification; D013792:Thalidomide / Q000494:pharmacology* / Q000627:therapeutic use; D000090324:Tumor Protein, Translationally-Controlled 1
D020533:Angiogenesis Inhibitors; D018076:DNA, Complementary; D012333:RNA, Messenger; C000715647:TPT1 protein, human; D000090324:Tumor Protein, Translationally-Controlled 1; D013792:Thalidomide; D012313:RNA